Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
NCT ID: NCT04966637
Last Updated: 2025-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54028 participants
OBSERVATIONAL
2021-06-01
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This project will use health data to find out if we can identify trends in health care use by individuals newly diagnosed with COPD. We will identify people that have COPD based on health records, and look back to find out about their health care use prior to their diagnosis. We will look at data related to doctors' visits, emergency department visits, hospital stays and medications. We want to use these markers to better understand what happens to people before they are diagnosed, and to find out if we can identify risk factors for a COPD diagnosis. We hope by doing this research we can better identify people at risk for COPD and ensure that they receive treatment early, which may improve their health outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Clinical Prediction Models to Improve Treatment for Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT05309356
The Canadian Cohort Obstructive Lung Disease
NCT00920348
Chronic Obstructive Pulmonary Disease Biomarker Study
NCT02050022
Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!
NCT01314807
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00722267
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Identifying a cohort of individuals with a new onset of COPD in the between April 1, 2016 and March 31, 2019.
2. To determine factors associated with a new diagnosis of COPD through using traditional mixed-model regression.
3. To evaluate whether information collected within administrative data can be used to create a prediction model for a COPD diagnosis.
4. To determine whether machine learning methodology improves the prediction of a new COPD diagnosis from administrative data.
Measures:
1. The cohort of individuals with COPD in Alberta has already been defined, and this data exists within the Alberta Health Services, Respiratory Health Strategic Clinical Network (RHSCN) dataset. It will be used to further identify individuals with a new diagnosis of COPD within the three year study time period.
2. In order to conduct this study, a variety of data sets will be used including:
* Inpatient Discharge Abstract Database;
* Practitioner Claims Database;
* Provincial Registry Database;
* Population Health Database and
* Pharmaceutical information Network
Project Hypothesis We anticipate individuals with a diagnosis of COPD in the last three years will have identifiable markers associated with lung disease in the five years prior to their diagnosis. These markers may include: diagnosis of acute respiratory disease (such as pneumonia, bronchitis, upper respiratory infections), increased health care utilization, and the use of medications such as antibiotics.
The project plan will address the specific project goals as follows:
1. Identifying a cohort of individuals with a new onset of COPD from April 1, 2016 to March 30, 2019. Through the RHSCN, a cohort of individuals with COPD has been identified of over 200,000 individuals with COPD in Alberta. This cohort will be refined to identify only those individuals that have been diagnosed within the specified time period. This time period was chosen due to data availability. Given our most recent data, we know that approximate 19,000 individuals have been diagnosed with COPD per year, over the last five years. Thus we can approximate that our dataset will include approximately 55,000 individuals with COPD diagnosed in a three year time period.
2. Retrospectively review the pattern of health care utilization for individuals with a new diagnosis of COPD in the five years prior to their diagnosis. The health care utilization (ED visits, hospitalization visits, physician visits) for each case in the cohort for the previous five years will be identified.
3. Explore the medication use for individuals with COPD for five years prior to their diagnosis. Lastly, the medication use for each case identified in the cohort during the time period five years prior to their diagnosis will be explored. The Pharmaceutical Information Network (PIN) database will be used to identify all medications (both respiratory and non-respiratory) for individuals in the cohort to assess medication use prior to diagnosis.
4. Working with the machine learning provider (AltaML) we will additionally conduct a machine learning based analysis to further explore this data set regarding the same variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individuals with COPD
This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019.
This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort
COPD cohort
as this a retrospective descriptive study no intervention will be administered to study participants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COPD cohort
as this a retrospective descriptive study no intervention will be administered to study participants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Incidence criteria included 5 year washout period in which they were not in Alberta, Canada but did not have any diagnosis of COPD
3. Individuals that meet this criteria with a new diagnosis in the last 3 years will be included in the cohort, thus individuals with their 'incident' diagnosis of COPD in the last three years will be included (01-APR-2016 to 31-MAR-2017, 01-APR-2017 to 31-MAR-2018; 01-APR-2018 to 31-MAR-2019)
Exclusion Criteria
2. Individuals that did not live in Alberta (with access to Alberta health care) during the five year washout period
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Alberta Health services
OTHER
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Stickland, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00097014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.